Skip to main content
FHIN OBSERVER / DEMO ENVIRONMENT READ-ONLY NETWORK ACCESS NO LIVE API CONNECTIONS
AimwellBio Intelligence Platform
CLIENT Trial Signal Shield Command Growth Enterprise Alumni Partner FHIN Observer Contributor Researcher Institutional Community ↗
FHIN Observer
247 active
32 regions
1,482 signals today
LIVE Dr. T. Nakamura
TN
Signals Viewed
89
+12 this week
Active Contributors
247
+18 this month
Network Regions Active
32
High activity
Research Areas Followed
5
Oncology, Immunology +3
LIVE NETWORK ACTIVITY
ASCO CONTRIBUTOR TRAFFIC RISING LIVE
Global Intelligence Activity Map · LIVE FROM ATLAS
HIGH ACTIVITY
MEDIUM
LOW
32 REGIONS ACTIVE
NETWORK PULSE
Loading network activity…
FHIN Signal Feed
Read Only
View all signals 🔒
READ ONLY
HIGH PRIORITY
Oncology Trial Site Enrollment Patterns — ASCO Prep
Submitter field intelligence: Major NCI-designated sites accelerating enrollment ahead of ASCO 2026. Specific targets in NSCLC and GBM arms showing strong momentum. Site-level detail includes principal investigator contact status, IRB submission timelines, and current cohort fill rates across…
🔒 Contributor details locked  ·  Full site-level detail available at Contributor tier
FHIN SIGNAL Oncology RESEARCH AI
Dr. M. Okonkwo · 4h ago · Contributor details locked
READ ONLY
MEDIUM PRIORITY
Biomarker Validation — Liquid Biopsy Commercial Uptake
Field observation: 3 major academic medical centers adopting ctDNA panels as standard of care for early-stage NSCLC monitoring. Volume up 40% Q1 2026 vs Q4 2025. Lab procurement data indicates…
🔒 Contributor details locked  ·  Institution-level data at Contributor tier
FHIN SIGNAL MARKET Oncology
S. Abramowitz · 9h ago
READ ONLY
TRENDING
EU Regulatory Horizon — EMA Oncology Submissions Wave
Intelligence from EU regulatory watchers: 12 oncology MAA submissions expected Q2 2026, highest single quarter in 5 years. Reviewer capacity concerns flagged. Basel contributor cluster is actively cross-referencing submission timing with…
🔒 Contributor details locked  ·  Full regulatory timeline at Contributor tier
FHIN SIGNAL Regulatory MARKET
Prof. L. Bergström · 14h ago
Signal feed filtered to Observer view  ·  Apply for Contributor access for full feed →
FHIN Contributor Pathway
Your progression ladder
01
Observer
CURRENT
02
Contributor
Submit signals
03
Researcher
Validation rights
04
Institutional
Network anchor
72% to Contributor — milestones remaining:
✓ 60+ signals viewed ✓ Profile complete → Submit application
FHIN Network 🔒
Contributor access required
SYNAPSE Sessions
🔒
Live SYNAPSE Sessions
Contributor access required
Institutional Collaboration
🔒
Institutional Panels
Available at Researcher tier
The network is active. You're on the edge of it.
Apply for Contributor Access
Join the network. Submit intelligence. Build your FHIN reputation. Observer access gives you the view — Contributor access gives you the seat at the table.
✓ Submit Intelligence
✓ Build Your FHIN Reputation
✓ Full Contributor Directory
✓ 100 Cortex Queries
✓ SYNAPSE Session Access
Invitation reviewed by FHIN editorial board · Most applicants approved within 48h
CORTEX AI — OBSERVER
20 queries left
Monthly usage14 / 20 used
CORTEX — OBSERVER MODE
Based on public FHIN observation signals, I can surface network patterns and publicly visible intelligence. Contributor-only site-level detail unavailable at Observer tier. Network confidence increased after contributor validation.
What are the top enrollment accelerations I should be watching in NSCLC?
CORTEX — OBSERVER MODE
Based on public FHIN observation signals: 3 NSCLC trials showing enrollment acceleration in the Boston and Tokyo clusters — Phase II/III assets in EGFR+ and KRAS G12C arms. ASCO 2026 deadline pressure is the common driver. Contributor-only site-level detail unavailable at Observer tier. View summarized trends →
Try:
Top Research Areas
Your FHIN focus
Oncology
88%
Immunology
72%
Regulatory
61%
Biotech Strategy
45%
Clinical Trials
38%
FHIN Top Contributors
Full directory 🔒
MO
Dr. M. Okonkwo
Oncology · Clinical Trials
84
SA
S. Abramowitz
Biomarkers · Commercial
79
CONTRIBUTOR DETAILS LOCKED
LB
Prof. L. Bergström
Regulatory Affairs · EMA
76
CONTRIBUTOR DETAILS LOCKED
KW
Dr. K. Williams
Immuno-oncology · KOL
73
CONTRIBUTOR DETAILS LOCKED
HT
H. Tanaka
Biotech Strategy · Asia-Pacific
71
CONTRIBUTOR DETAILS LOCKED
Observer Profile
Building…
480
score
Dr. Taro Nakamura
Research Physician · Keio University
Your observer profile is building…
Top Research Interests
Oncology Immunology Regulatory Biotech Strategy NSCLC
Member SinceFeb 2026
Signals Viewed89
Days Active18
Network ParticipationObserver
Contributor Score— Earn at Contributor tier
Ready to Go Deeper?
Join the FHIN as a Contributor to unlock full signal details, submit intelligence, build your reputation, and access the complete network — including Cortex full access, validation tools, and premium analytics.
Submit Intelligence Build AI Score Full Directory Access Unlimited Cortex Queries Earn Network Credits
Apply for Contributor Access
100+ CONTRIBUTORS · 32 REGIONS
ONE INTELLIGENCE NETWORK